Clinical Trials Logo

Fibroma clinical trials

View clinical trials related to Fibroma.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06219733 Recruiting - Dermoid Clinical Trials

Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

MP-VAC-206
Start date: November 23, 2021
Phase: Phase 2
Study type: Interventional

Vactosertib and imatinib combination in patients with advanced desmoid tumor/aggressive fibromatosis (DT/AF) compared with imatinib monotherapy

NCT ID: NCT06204198 Recruiting - Clinical trials for Aggressive Fibromatosis of Abdominal Wall (Disorder)

Clinicopathological Features and Molecular Typing of Invasive Fibroma of Abdominal Wall

Start date: September 1, 2023
Phase:
Study type: Observational

Aggressive fibromatosis, also known as desmoid fibromatosis or desmoid tumor, is a fibrous tumor that occurs in the fascia, aponeurosis, or deep soft tissue and is formed by excessive proliferation of fibroblasts and myofibroblasts. At present, the disease is considered to be a borderline tumor. Due to the unclear boundary of the tumor, it often grows into the surrounding adjacent tissues, which is difficult to remove completely and easy to relapse. It has been reported that nuclear β-catenin expression and CTNNB1 gene mutation can be used for the differential diagnosis of aggressive fibromatosis from other spindle cell lesions. At present, there is a lack of multicenter retrospective clinical study of this disease, and there is no literature report on the postoperative quality of life of this kind of patients. This study intends to further explore the clinicopathological features, prognosis and molecular typing of abdominal wall aggressive fibroma by retrospective analysis of the case data of multiple hospitals, as well as sequencing analysis of the retained specimens and paraffin specimens from previous operations, to study the high risk factors for recurrence of the disease, and to further comprehensively analyze the impact of abdominal wall aggressive fibroma surgery on the quality of life of patients through follow-up.

NCT ID: NCT06151197 Recruiting - Clinical trials for Plantar Fibromatosis

Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

STRIDE
Start date: November 28, 2023
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).

NCT ID: NCT05500391 Recruiting - Glioma Clinical Trials

Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring

SUR-CAN
Start date: February 28, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan, established for each patient according to national guidelines, when the surveillance is conducted in person by a hospital-based physician (control arm) or remotely by a trained nurse (experimental arm).

NCT ID: NCT05440240 Recruiting - Neoplasms Clinical Trials

Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture

Start date: January 10, 2023
Phase: Phase 4
Study type: Interventional

Comparing percutaneous needle fasciotomy +/- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.

NCT ID: NCT04851119 Recruiting - Melanoma Clinical Trials

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Start date: November 8, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.

NCT ID: NCT04281381 Recruiting - Clinical trials for Desmoid Fibromatosis

Observing People With Desmoid-Type Fibromatosis

Start date: February 19, 2020
Phase:
Study type: Observational

The purpose of this study is to closely observe people with desmoid-type fibromatosis over 1 months.

NCT ID: NCT03605199 Recruiting - Chondroblastoma Clinical Trials

Denosumab in Subjects With Giant Cell Rich Tumors of Bone

Start date: June 18, 2018
Phase: Phase 2
Study type: Interventional

An open-label, multi-center, phase 2 study of the efficacy of denosumab in subjects with giant cell rich tumors of bone. The population will consist of subjects with the following tumor types: aneurysmal bone cysts (ABC), giant cell granuloma (GCG) and other giant cell rich lesions (primary bone, non-malignant).

NCT ID: NCT03550703 Recruiting - Leiomyoma Clinical Trials

Open Label Immunotherapy of Myoma

V3-myoma
Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

Myoma of the uterus or uterine fibroids are benign tumors that appears in the myometrium or the muscular layer of the uterus. It is one of the most common diseases in pre-climax women, reaching 12-25% of all gynecological diseases. There is an opinion that the true prevalence of myoma is much larger and reaches up to 80%, i.e., practically every second woman has it, often without knowing about. For the treatment of MM, surgical removal of the nodes or removal of the uterus is used. In addition, GnRH-agonist therapy is practiced, as well as embolization to block blood flow in the tumor. We propose to evaluate the immunotherapy approach in an open label Phase II study in 20 women with myoma, for whom no alternative therapy is available.

NCT ID: NCT02610985 Recruiting - Fibroma, Bleeding Clinical Trials

2-D and 3-D Laparoscopic Hysterectomy

Start date: September 2016
Phase: N/A
Study type: Interventional

Background: No randomised trials have been conducted, and only a single retrospective study exists comparing 3D and 2D laparoscopic hysterectomy. In that study, operative time for hysterectomy was significantly lower for 3D compared to 2D conventional laparoscopy. Complication rates were similar for the two groups. Thus, although one out of nine women is hysterectomized and although laparoscopy is one of the recommended routes of surgery, evidence whether to choose 2D laparoscopy, 3D laparoscopy is sparse. Objective: To compare pain and recurrence to usual activity level. Secondary to compare complications during the operation, postoperative complications, time to return to work, length of hospital stay and operative time. Design: Investigator-initiated, blinded, randomised controlled trial. Intervention description: Operative procedures follow the same principles and the same standard whether the surgeon's vision is 2D or 3D. Trial size Roskilde/Herlev Hospital, Denmark: 200 patients in each arm of the study.